NCT07070193Not yet recruiting
Longitudinal Cohort Study on Immune Thrombocytopenia Complicated With Acute Ischemic Stroke
Retrospective and Prospective Longitudinal Observational Study on Immune Thrombocytopenia Complicated With Acute Ischemic Stroke
Source: ClinicalTrials.gov · Last updated 17 Jul 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
Immune thrombocytopenia (ITP) is an acquired bleeding disorder mediated by immune-related platelet destruction and impaired platelet production. Immune thrombocytopenia may increase the risk of cerebral infarction and represents a relatively uncommon etiology of acute ischemic stroke. This disease is associated with high disability and mortality rates, poses significant therapeutic challenges, and constitutes a serious threat to human health. Therefore, research on the diagnosis, treatment, and prognosis of ITP combined with acute ischemic stroke is of great significance for improving patients' quality of life and survival outcomes. However, most current hematologic cohort studies are based on single-center or limited multicenter sample sizes, lacking comprehensive and large-scale prospective cohort studies. Our center plans to conduct a large-sample, combined retrospective and prospective longitudinal cohort study. This study will register patients' basic information and diagnosis, follow up with patients through questionnaires, telephone calls, video consultations, online platforms, and in-person visits to record treatment and comorbidity data, collect prognostic information, and retrieve hospitalization and outpatient costs through medical record systems. The study aims to provide comprehensive data on the incidence, treatment, prognosis, and healthcare costs of ITP patients with acute ischemic stroke in China.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 500 (estimated)
- First submitted
- 8 Jul 2025
- Start date
- 10 Jul 2025
- Primary completion date
- 31 Dec 2035
- Lead sponsor
- Peking University People's Hospital
- Diseases
- Stroke
- NCT number
- NCT07070193
What you commit to
- Study type: Observational
- Planned participants: 500
- From 10 Jul 2025 to the primary completion date, 31 Dec 2035
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- For any reason, such as the occurrence of severe mental disorders, the follow-up information may be unavailable;
Other
- Patients deemed unsuitable for the study by the researchers.
Who the study is looking for
- Diagnosed with immune thrombocytopenia, and subsequently identified patients with acute ischemic stroke.
- Since January 1, 2005, patients who received treatment at Peking University People's Hospital.
Sex: All · Accepts healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.